Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney DiNardo, Lucia Masarova, Tapan Kadia, Rebecca S. Garris, Farhad Ravandi, Hagop Kantarjian

Blood (2024) 143 (5): 417–421.

https://doi.org/10.1182/blood.2023022330

Published: 2024

Includes: Supplemental data

Journal Articles

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Blood (2019) 133 (10): 1011–1019.

https://doi.org/10.1182/blood-2018-10-879429

Published: 2019

Includes: Supplemental data

Journal Articles

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

Blood (2017) 129 (5): 572–581.

https://doi.org/10.1182/blood-2016-07-726588

Published: 2017

Includes: Supplemental data

Journal Articles

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Nitin Jain, Audrey V. Lamb, Susan O’Brien, Farhad Ravandi, Marina Konopleva, Elias Jabbour, Zhuang Zuo, Jeffrey Jorgensen, Pei Lin, Sherry Pierce, Deborah Thomas, Michael Rytting, Gautam Borthakur, Tapan Kadia, Jorge Cortes, Hagop M. Kantarjian, Joseph D. Khoury

Blood (2016) 127 (15): 1863–1869.

https://doi.org/10.1182/blood-2015-08-661702

Published: 2016

Includes: Supplemental data

Journal Articles

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Paolo Strati, Michael J. Keating, Susan M. O'Brien, Jan Burger, Alessandra Ferrajoli, Nitin Jain, Francesco Paolo Tambaro, Zeev Estrov, Jeffrey Jorgensen, Pramoda Challagundla, Stefan H. Faderl, William G. Wierda

Blood (2014) 123 (24): 3727–3732.

https://doi.org/10.1182/blood-2013-11-538116

Published: 2014

Includes: Supplemental data

Journal Articles

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Madeleine Duvic, MD, Lauren Pinter-Brown, Francine Foss, MD, Lubomir Sokol, MD, PhD, Jeffrey Jorgensen, MD, PhD, Xiao Ni, MD, PhD, Pramoda Challagundla, MS, Meghali Goswami, BS, Karen Dwyer, Nehal Mohamed, PhD, Youn H Kim, MD

Blood (2012) 120 (21): 3697.

https://doi.org/10.1182/blood.V120.21.3697.3697

Published: 2012

Journal Articles

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Farhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Charles Koller, Pramoda Challagundla, Sergernne York, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Deborah Thomas, Michael Keating, Hagop Kantarjian

Blood (2011) 118 (14): 3818–3823.

https://doi.org/10.1182/blood-2011-04-351502

Published: 2011

Journal Articles

Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia

Farhad Ravandi, MD, Jeffrey Jorgensen, MD, PhD, Susan O'Brien, MD, Deborah A Thomas, MD, Stefan Faderl, MD, Sergernne York, RN, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Sherry Pierce, RN, BS, Michael Keating, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2458.

https://doi.org/10.1182/blood.V116.21.2458.2458

Published: 2010

Journal Articles

Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients

Madeleine Duvic, MD, Lauren Pinter-Brown, MD, Francine M Foss, MD, Lubomir Sokol, MD, PhD, Jeffrey Jorgensen, MD, PhD, George L Spitalny, PhD, Youn H. Kim, MD

Blood (2010) 116 (21): 962.

https://doi.org/10.1182/blood.V116.21.962.962

Published: 2010

Journal Articles

Significance of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) In Adults with De Novo Acute Lymphoblastic Leukemia (ALL) After Therapy with the Modified Hyper-CVAD Regimen

Deborah A. Thomas, MD, Susan O'Brien, MD, Jeffrey Jorgensen, MD, PhD, Sa A. Wang, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Rebecca Garris, BA, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2145.

https://doi.org/10.1182/blood.V116.21.2145.2145

Published: 2010

Journal Articles

Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Farhad Ravandi, MD, Deborah A Thomas, MD, Susan O'Brien, MD, Stefan Faderl, MD, Jeffrey Jorgensen, MD, PhD, Rajyalakshmi Luthra, PhD, Dan Jones, MD, PhD, Rebecca Garris, BA, Jorge E. Cortes, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2127.

https://doi.org/10.1182/blood.V116.21.2127.2127

Published: 2010

Journal Articles

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph + ) acute lymphoblastic leukemia

Farhad Ravandi, Susan O'Brien, Deborah Thomas, Stefan Faderl, Dan Jones, Rebecca Garris, Samuel Dara, Jeffrey Jorgensen, Partow Kebriaei, Richard Champlin, Gautam Borthakur, Jan Burger, Alessandra Ferrajoli, Guillermo Garcia-Manero, William Wierda, Jorge Cortes, Hagop Kantarjian

Blood (2010) 116 (12): 2070–2077.

https://doi.org/10.1182/blood-2009-12-261586

Published: 2010

Journal Articles

Minimal Residual Disease (MRD) after Frontline Therapy in Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) Treated on Two Separate Regimens.

Michael Rytting, MD, Deborah Thomas, M.D., Jeffrey Jorgensen, M.D., Hagop Kantarjian, M.D., Rebecca Garris, Brenda Muriera, R.N., Susan O’Brien, M.D.

Blood (2007) 110 (11): 4344.

https://doi.org/10.1182/blood.V110.11.4344.4344

Published: 2007

Journal Articles

Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission.

Farhad Ravandi, Jean-Pierre Issa, Stefan Faderl, Guillermo Garcia-Manero, Mary Hood, Jeffrey Jorgensen, Ming Lee, Susan O’Brien, Elihu Estey, Gautam Borthakur, Alessandra Ferrajoli, Srdan Verstovsek, Jorge Cortes, Hagop Kantarjian

Blood (2007) 110 (11): 2859.

https://doi.org/10.1182/blood.V110.11.2859.2859

Published: 2007

Journal Articles

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Farhad Ravandi, MD, Deborah Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Devri Brown, Rebecca Garris, Gautam Borthakur, MD, Jan Burger, MD, Partow Kebriaei, MD, Jeffrey Jorgensen, MD, Dan Jones, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 2814.

https://doi.org/10.1182/blood.V110.11.2814.2814

Published: 2007

Journal Articles

Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab.

Farhad Ravandi-Kashani, MD, Susan O’Brien, MD, Keating Michael, MD, Dan Jones, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, William Wierda, MD, Shirley Odinga, Sherry Pierce, Charles Koller, MD, Srdan Verstovsek, MD, Jeffrey Jorgensen, MD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 3258.

https://doi.org/10.1182/blood.V106.11.3258.3258

Published: 2005

NARROW

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia

Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients

Significance of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) In Adults with De Novo Acute Lymphoblastic Leukemia (ALL) After Therapy with the Modified Hyper-CVAD Regimen

Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph + ) acute lymphoblastic leukemia

Minimal Residual Disease (MRD) after Frontline Therapy in Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) Treated on Two Separate Regimens.

Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission.

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only